| Ginseng for Multiple Sclerosis Related Fatigue |
| IRB# 1357 |
| Principal Investigator: Ruth Whitam, M.D. |
| The MS Center of Oregon is currently recruiting study subjects to enroll in a placebo controlled cross-over design trial that will study the effect of an American Ginseng extract on multiple sclerosis related fatigue.
To enroll in the study, subjects must be between the ages of 18 and 65 years, carry a diagnosis of multiple sclerosis and have problems with fatigue for greater than two months.
Participation in the study requires that subjects undergo clinical assessments at OHSU on seven separate occasions over a 17-week period. There will be two 6-week treatment periods, separated by a 2-week washout period. All subjects take ginseng for one treatment period and placebo for one treatment period. Those participating in the study will be asked to wear activity monitors at the waist and wrist for several weeks over the course of the study. Clinical assessments will be done at the beginning and end of each treatment period and will involve physical exams, questionnaires, blood draws and collection of saliva samples.
There will be no financial costs to subjects who choose to participate in this study.
If you would like further information about this study or to refer a subject, please contact:
The MS Center of Oregon Research Line at (503) 494-7241
This study will take place in association with the MS Center of Oregon at Oregon Health & Science University in Portland, Oregon. |
| Treatment of Multiple Sclerosis-Specific Fatigue with Traditional Chinese Medicine (TCM): A Randomized, Placebo-controlled Pilot Study. |
| IRB# 6788 |
| Principal Investigator: Richard Hammerschlag, PhD. |
| Research participants are needed for a 12-week collaborative study between the OHSU MS Center (IRB#6788) and the Oregon College of Oriental Medicine (OCOM IRB#01-004) to test acupuncture and herbs for treating MS-related fatigue.
Participants must: To determine if you qualify, please contact Meggan Baumgartner, OCOM Research Coordinator at (503) 253-3443 ext 231. |
| Double-blind Placebo Controlled Pilot Trial of Memantine for Cognitive Impairment in Multiple Sclerosis. |
| IRB# 8211 |
| Principal Investigator: Dennis Bourdette, MD |
| The MS Center of Oregon is currently recruiting patients to enroll in a clinical trial that will study the cognitive function in patients with multiple sclerosis. To enroll in the study: -
Patients must carry a diagnosis of multiple sclerosis, and be between 18 and 60 years of age. -
Participation in the study requires that patients undergo clinical assessment at OHSU on five separate occasions over a 21-week period. These clinical assessments involve physical exams, a questionnaire, blood draws, and mental function tests. -
Enrolled patients will be treated with either Memantine or placebo (sugar pill) for 18 weeks.
There will be no financial costs to patients who choose to participate in this study. |
| Fish Oil as an Adjunct Therapy for Depression in MS |
| IRB# 8295 |
| Principal Investigator: Lynne Shinto, ND |
| The MS Center of Oregon at Oregon Health & Science University is looking for people with a confirmed diagnosis of relapsing remitting MS who are suffering from depression. The purpose of the study is to determine if taking omega-3 fatty acids helps with symptoms of depression in people with MS. In addition we will determine if omega-3 fatty acids decrease blood levels of substances that are associated with MS and depression You may be eligible to participate in the study if you meet the all of the following criteria: -
18-65 years old -
Have a diagnosis of relapsing remitting MS -
On a stable dose of Copaxone, Betaseron or Avonex -
On a stable dose of anti-depressant medication -
Have not had an MS relapse or received corticosteroid treatment 1 month prior to enrollment -
Have not eaten more than one 6 oz serving of fish per week 1 month prior to enrollment -
Have not taken fish oil or omega-3 fatty acid supplementation 1 month prior to enrollment -
Not pregnant -
Have no other significant health conditions (like coronary heart disease, uncontrolled diabetes mellitus, liver disease, severe psychiatric disorders) -
Not participating in any other studies
This is a three-month pilot study in which 60 participants will be randomly assigned to receive either fish oil capsules (which have high amounts of omega-3 fatty acids) or placebo oil capsules. The study requires 8 visits to MS Center at OHSU. The research study will pay for all costs associated with the participation in this study. You will be responsible for any expenses that have to do with other aspects of your participation such as childcare and transportation. If you meet the eligibility requirements described above and are interested in participating in this study please call Rachel Frank at (503) 494-7963. |
0 Comments:
Post a Comment
<< Home